Hemab Therapeutics (NASDAQ:COAG) Shares Up 7.6% - Time to Buy?

Key Points

• Hemab Therapeutics shares rose 7.6% to $43.15, although trading volume was 57% below the stock’s average daily volume.
• Analyst sentiment is generally positive, with five Buy ratings, one Hold and one Sell; the average price target is $51.40, while HC Wainwright and Wedbush raised their targets to $60 and $64, respectively.
• The clinical-stage biotech missed quarterly earnings expectations, reporting a loss of $0.80 per share versus the $0.63 consensus estimate. Hedge funds, including Citadel Advisors, recently established sizable positions in the company.

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report)'s share price was up 7.6% during trading on Wednesday . The company traded as high as $43.23 and last traded at $43.15. 139,826 shares traded hands during trading, a decline of 57% from the average daily volume of 323,800 shares. The stock had previously closed at $40.11.

Analysts Set New Price Targets

Several equities analysts recently weighed in on COAG shares. HC Wainwright increased their price target on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. The Goldman Sachs Group started coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set a "buy" rating and a $36.00 target price for the company. Evercore began coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued an "outperform" rating and a $50.00 price target on the stock. Wedbush increased their price target on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings started coverage on Hemab Therapeutics in a report on Thursday, August 13th. They issued a "sell (d+)" rating for the company. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $51.40.

Hemab Therapeutics Price Performance

The stock has a market capitalization of $2.02 billion and a PE ratio of -1.74. The company's fifty day moving average is $46.51.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.17). Analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -3.09 EPS for the current year.

Hedge Funds Weigh In On Hemab Therapeutics

A number of hedge funds have recently bought and sold shares of COAG. Citadel Advisors LLC purchased a new stake in shares of Hemab Therapeutics in the second quarter valued at approximately $19,226,000. Braidwell LP purchased a new stake in Hemab Therapeutics in the 2nd quarter worth $5,877,000. Opaleye Management Inc. acquired a new position in Hemab Therapeutics during the second quarter worth $1,750,000. The Manufacturers Life Insurance Company purchased a new position in Hemab Therapeutics during the second quarter valued at $688,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Hemab Therapeutics in the second quarter valued at about $230,000.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious and underserved bleeding disorders. The company aims to create therapies that address limitations of existing approaches, including the need for frequent administration and the challenges associated with complex blood-product-based treatments.

Its lead investigational program, HMB-001, is being developed for Glanzmann thrombasthenia, a rare inherited disorder in which platelets do not function properly and can cause severe bleeding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.